Guardant Health, Inc.
GH
Κατάταξη σε μετοχές
#1078
Guardant Health, Inc., established in Redwood City, California, in 2011, is a... Guardant Health, Inc., established in Redwood City, California, in 2011, is a precision oncology company that delivers a range of diagnostic blood tests, comprehensive data sets, and advanced analytical solutions both within the United States and internationally. For patients with advanced-stage cancer, the company's core offerings include several liquid biopsy-based tests such as Guardant360 (available in LDT and CDx versions) and GuardantOMNI. Complementing these diagnostic tools, Guardant Health also provides GuardantINFORM, an in-silico research platform leveraging an extensive clinical-genomic liquid biopsy dataset derived from advanced cancer patients. Innovation is a key focus, with the company currently developing the LUNAR-2 test, designed for the early detection of colorectal cancer in eligible asymptomatic individuals. Another emerging solution in development is GuardantConnect, an integrated software platform intended to link biopharmaceutical and clinical clients by connecting patients whose Guardant360 tests reveal actionable alterations with potentially relevant clinical trials. Furthermore, Guardant Health offers the Guardant Reveal Test, which aids in selecting neoadjuvant and adjuvant treatments for early-stage cancer patients. Its portfolio also includes a Guardant360 product for tissue genotyping and Guardant-19 for novel coronavirus detection. The company extends its expertise to biopharmaceutical companies and medical institutions through various development services, encompassing companion diagnostic development, regulatory approval support, clinical study management (including setup, monitoring, and maintenance), testing development, and kit fulfillment.
Τιμή μετοχής
$162.03
Τελευταίος συγχρονισμός: 2026-10-20
Κεφαλαιοποίηση
$21.74B
Αλλαγή (1 ημέρα)
2.63%
Αλλαγή (1 έτος)
140.01%
Χώρα
US
Εμπόριο Guardant Health, Inc. (GH)
Κατηγορία
Healthcare
Έσοδα για την Guardant Health, Inc. (GH)
Έσοδα τον Jun 2026 TTM: $1.18B
Σύμφωνα με τις τελευταίες οικονομικές αναφορές της Guardant Health, Inc., τα τρέχοντα έσοδα της εταιρείας (TTM) είναι $1.18B. Το 2023, η εταιρεία είχε έσοδα $563.95M αύξηση σε σχέση με τα έσοδα του έτους 2022, τα οποία ήταν $449.54M. Τα έσοδα είναι το συνολικό ποσό που παράγει μια εταιρεία από τις πωλήσεις προϊόντων ή υπηρεσιών. Σε αντίθεση με τα κέρδη, δεν αφαιρούνται έξοδα.
Ιστορικό εσόδων για την Guardant Health, Inc. από 2016 έως 2026
Έσοδα στο τέλος κάθε έτους
| Έτος | Έσοδα | Αλλαγή |
|---|---|---|
| 2026 (TTM) | $1.18B | 60.09% |
| 2024 | $739.02M | 31.04% |
| 2023 | $563.95M | 25.45% |
| 2022 | $449.54M | 20.31% |
| 2021 | $373.65M | 30.32% |
| 2020 | $286.73M | 33.75% |
| 2019 | $214.38M | 136.52% |
| 2018 | $90.64M | 81.85% |
| 2017 | $49.84M | 97.40% |
| 2016 | $25.25M | 0.00% |
Έσοδα για παρόμοιες εταιρείες ή ανταγωνιστές
| Εταιρεία | Έσοδα | Διαφορά Εσόδων | Χώρα |
|---|---|---|---|
| $46.34B | 3,816.47% |
US
|
|
| $25.11B | 2,022.13% |
US
|
|
| $2.71B | 128.81% |
US
|
|
| - | - |
CN
|
|
| $7.37B | 523.11% |
US
|
